Bifogade filer
SANIONA Annual Report 2023 UK
Kurs
-1,09%
Likviditet
0,61 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-02-27 | 08:00 | Bokslutskommuniké 2024 |
| 2024-11-28 | 08:00 | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-29 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-27 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2024-05-25 | - | Årsstämma |
| 2024-02-29 | - | Bokslutskommuniké 2023 |
| 2024-01-16 | - | Extra Bolagsstämma 2024 |
| 2023-11-30 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | Årsstämma |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-24 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-11-17 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-08-18 | - | Extra Bolagsstämma 2022 |
| 2022-05-27 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2022-05-25 | - | Årsstämma |
| 2022-05-25 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-09-16 | - | Extra Bolagsstämma 2021 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2021-05-26 | - | Årsstämma |
| 2021-05-26 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-17 | - | Bokslutskommuniké 2020 |
| 2020-11-30 | - | Kvartalsrapport 2020-Q3 |
| 2020-10-23 | - | Extra Bolagsstämma 2020 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-28 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2020-05-06 | - | Årsstämma |
| 2020-05-06 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-07 | - | Extra Bolagsstämma 2019 |
| 2020-02-07 | - | Bokslutskommuniké 2019 |
| 2019-11-13 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-31 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2019-05-29 | - | Årsstämma |
| 2019-05-29 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-11-14 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2018-05-24 | - | Årsstämma |
| 2018-05-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-21 | - | Bokslutskommuniké 2017 |
| 2018-01-19 | - | Extra Bolagsstämma 2018 |
| 2017-11-15 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-23 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-24 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2017-05-23 | - | Årsstämma |
| 2017-05-11 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-21 | - | Bokslutskommuniké 2016 |
| 2016-10-13 | - | Extra Bolagsstämma 2016 |
| 2016-05-11 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2016-05-10 | - | Årsstämma |
| 2016-05-10 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-19 | - | Bokslutskommuniké 2015 |
| 2015-11-20 | - | Kvartalsrapport 2015-Q3 |
| 2015-09-04 | - | Extra Bolagsstämma 2015 |
| 2015-08-31 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-21 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2015-05-20 | - | Årsstämma |
| 2015-05-20 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-20 | - | Bokslutskommuniké 2014 |
| 2014-11-21 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-22 | - | Kvartalsrapport 2014-Q2 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders today announced that the English version of the Annual Report for 2023 is now available on the company’s website, www.saniona.com.
For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com
About Saniona
Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona’s epilepsy pipeline features SAN711, a Phase 2-ready candidate drug targeting absence seizures, SAN2219 for acute repetitive seizures, and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine, Saniona’s most advanced candidate, is progressing towards regulatory approval for obesity in Mexico through a partnership with Medix. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona has esteemed partners, including Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market. For more information, please visit www.saniona.com.
This information is information that Saniona AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-30 12:45 CEST.
Attachments
SANIONA Annual Report 2023 UK